Skip to main content

Arbutus Biopharma Corp 10-Q for FY2026 Q3

Arbutus Biopharma Corp (ABUS)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Arbutus Biopharma Corp filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Arbutus Biopharma Corporation said the FDA lifted its clinical hold on AB-101’s IND application in October 2026, allowing additional clinical development in the United States. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$299K
down 43.5% from $529K a year earlier
Net income
$59.12M
compared with a net loss of $7.74M a year earlier
Diluted EPS
$0.30
compared with -$0.04 a year earlier